Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study

Abstract

The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin and novel oral anticoagulants: inhibitor of coagulation factor Xa rivaroxaban, apixaban, and the direct thrombin inhibitor dabigatran. There are results of a ROCKET AF subanalysis which compared rivaroxaban and warfarin in patients with AF after IS or TIA. It is noted that widespread clinical use of oral anticoagulants for atrial fibrillation could result in a significant reduction of IS morbidity and mortality in this country.

Keywords

• вторичная профилактика ишемического инсульта
• фибрилляция предсердий
• пероральные антикоагулянты
• апиксабан
• дабигатран
• ривароксабан
• субанализ исследования rocket af
• secondary prevention of ischemic stroke
• atrial fibrillation
• oral anticoagulants
• apixaban
• dabigatran
• rivaroxaban
• rocket af subanalysis